Skip to main content
Premium Trial:

Request an Annual Quote

CytRx Licenses RNAi Technology for ALS Research from U Mass Med School

NEW YORK, June 30 - CytRx today said it has signed an exclusive, worldwide, royalty-bearing license agreement with the University of Massachusetts Medical School (UMMS) to use UMMS's RNA interference technology in the development of a treatment for amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease.

 

The approach, developed by Zuoshang Xu, associate professor of biochemistry and molecular pharmacology at UMMS, uses RNAi gene silencing to search for mutant genes that cause ALS.

 

"While several promising treatments are being developed for ALS, the specificity and power of RNAi technology could advance these efforts significantly," said Steven Kriegsman, CytRx CEO.

 

Financial details of the licensing agreement were not disclosed.

 

The agreement is part of a broad strategic alliance between CytRx and UMMS that also includes exclusive licensing agreements for the use of RNAi in the development of therapeutic products to treat obesity and type II diabetes.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.